- Home
- FURY vs OTLK Comparison
FURY vs OTLK Comparison
Compare FURY & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- OTLK
- Stock Information
- Founded
- FURY 2008
- OTLK 2010
- Country
- FURY Canada
- OTLK United States
- Employees
- FURY N/A
- OTLK N/A
- Industry
- FURY Precious Metals
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FURY Basic Materials
- OTLK Health Care
- Exchange
- FURY Nasdaq
- OTLK Nasdaq
- Market Cap
- FURY 57.0M
- OTLK 48.3M
- IPO Year
- FURY N/A
- OTLK 2016
- Fundamental
- Price
- FURY $0.37
- OTLK $1.44
- Analyst Decision
- FURY Strong Buy
- OTLK Strong Buy
- Analyst Count
- FURY 1
- OTLK 5
- Target Price
- FURY $1.20
- OTLK $10.20
- AVG Volume (30 Days)
- FURY 143.9K
- OTLK 278.3K
- Earning Date
- FURY 05-16-2025
- OTLK 05-19-2025
- Dividend Yield
- FURY N/A
- OTLK N/A
- EPS Growth
- FURY N/A
- OTLK N/A
- EPS
- FURY N/A
- OTLK N/A
- Revenue
- FURY N/A
- OTLK N/A
- Revenue This Year
- FURY N/A
- OTLK N/A
- Revenue Next Year
- FURY N/A
- OTLK $288.46
- P/E Ratio
- FURY N/A
- OTLK N/A
- Revenue Growth
- FURY N/A
- OTLK N/A
- 52 Week Low
- FURY $0.35
- OTLK $0.87
- 52 Week High
- FURY $0.56
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- FURY 44.49
- OTLK 48.17
- Support Level
- FURY $0.38
- OTLK $1.52
- Resistance Level
- FURY $0.41
- OTLK $1.62
- Average True Range (ATR)
- FURY 0.02
- OTLK 0.10
- MACD
- FURY -0.00
- OTLK -0.01
- Stochastic Oscillator
- FURY 29.12
- OTLK 27.27
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.